CoreWeave CFO Sells $6M in Stock, Reinforcing Caution Amid Leverage Concerns

What happened

CoreWeave's CFO Nitin Agrawal sold nearly $6 million in stock last week, adding to a cluster of insider sales in late May that included the CEO and directors. This follows a Q1 report showing rapid capacity buildout with $7.7B in capex and $25.1B in debt, while quarterly interest expense guidance of $650M–$730M consumes most operating income. The company's latest financing includes a 1.35x DSCR covenant that will tighten equity's margin for error after September 2026. The insider sales, while not unusual for liquidity purposes, occur as the stock trades near $104, above the report's attractive entry of $85. The pattern suggests insiders are monetizing at a time when delivery delays or covenant stress could pressure the stock.

Implication

The CFO sale is a data point that aligns with the thesis that execution and balance-sheet risks are underpriced. Combined with heavy leverage and a covenant test ahead, investors should demand evidence of on-time delivery and stable interest costs before establishing positions. The sale does not change the fundamental view but makes the wait more prudent until Q2 results confirm FY2026 targets.

Thesis delta

The cluster of insider sales, including the CFO's $6M dump, raises the probability that near-term execution risks are material and that insiders are signaling limited upside from current levels. This does not alter the base-case scenario of $110 value but tilts the risk-reward toward caution until Q2 delivery evidence is available. The thesis now weights the bear case (25% chance of $70) slightly higher given insider behavior.